Ireland-based medical technology firm PMD Solutions is set to offer its RespiraSense respiratory rate (RR) monitor through the National Health Service’s (NHS) Innovation Accelerator (NIA) programme in the UK.
NIA comprises 15 Academic Health Science Networks (AHSNs) and works towards providing innovations across 799 NHS organisations.
RespiraSense is designed to continuously and accurately measure RR by analysing respiration mechanics to provide real-time and critical data.
Leveraging the firm’s Sensor Technology, the monitoring device comprises the Sensor, Lobe and RespiraSense Software Application.
The single-use Sensor is attached to the Lobe that uses algorithms to process breathing signal, which is transmitted to a tablet computer.
RespiraSense then displays accurate, easy-to-read RR measurements on the tablet and confidentially notifies medical professionals in case of increased levels exceeding preset thresholds.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
The wireless technology also enables recording and retrieval of the vital information.
PMD additionally integrated a scan-to-connect feature to ensure secure retrieval of a patient’s information by medical staff.
PMD Solutions CEO Myles Murray said: “Respiratory rate is the earliest indicator of patient deterioration, yet it is the most poorly measured.
“RespiraSense has demonstrated that it can detect deterioration up to 12h earlier than the standard of care so we now look forward with great anticipation to delivering the very best in RR innovation across the 799 NHS organisations in the UK.”
Founded in 2011, the firm develops respiratory rate wearable solutions, as well as sleep and primary care screening services to identify dysfunctional breathing.